Chemotherapy-induced Anemia

• FDA approval · 2018-05-15
  FDA Approved: RETACRIT — Original Application (Vifor (International) Inc.)

  The FDA approved Retacrit (epoetin alfa-epbx) under Original Application BLA125545, establishing it as a biosimilar to epoetin alfa. The app…

• FDA approval · 2013-03-27
  FDA Approved: PROCRIT — Supplemental Application (Janssen Products, LP)

  FDA approved Janssen Products, LP's supplemental application for PROCRIT (erythropoietin), updating the product labeling under BLA103234.

• FDA approval · 2011-06-24
  FDA Approved: ARANESP — Supplemental Application (Amgen, Inc)

  FDA approved a supplemental application for ARANESP (darbepoetin alfa) submitted by Amgen, Inc.

• FDA approval · 2008-03-07
  FDA Approved: PROCRIT — Supplemental Application (Janssen Products, LP)

  FDA approved a supplemental application for PROCRIT (epoetin alfa) submitted by Janssen Products, LP.

• FDA approval · 2007-12-17
  FDA Approved: ARANESP — Supplemental Application (Amgen, Inc)

  FDA approved Amgen's supplemental application for ARANESP (darbepoetin alfa), resulting in an updated approval status for the product throug…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2007-11-08
  FDA Approved: ARANESP — Supplemental Application (Amgen, Inc)

  FDA approved a supplemental application for ARANESP (darbepoetin alfa) from Amgen, Inc.

• FDA approval · 2007-03-09
  FDA Approved: ARANESP — Supplemental Application (Amgen, Inc)

  FDA approved a supplemental application for ARANESP (darbepoetin alfa) from Amgen, Inc.